Almirall is actively searching new in-licensing opportunities, mainly products in clinical development phases in specialist areas covering Europe, US, Canada and Mexico. Thanks to a defined therapeutic focus and a straightforward initial assessment process, we are able to react rapidly and move negotiations forward in a short time.
Our experience allows us to offer significant added value to companies who want to partner with a dynamic and growing global company, capable of successfully marketing its assets and willing to give the right priority to in-licensed projects.
Almirall's business model is a successful combination of R&D and corporate development, where in-licensing will continue to be a key driver of future transformation for our company. Our most recent in-licensing deals (i.e. Sativex, Sitagliptin, Silodosin) illustrate Almirall's potential to establish alliances with companies ranging from biotech to Big Pharma.
In-Licensing in Therapeutic Areas
Almirall is actively searching new in-licensing products, mainly in the following therapeutic areas:
- Dermatology, with focus on non-melanoma skin cancer, atopic dermatitis/eczema, psoriasis, acne, onychomycosis and other related indications, at any stage of development.
- Multiple Sclerosis (MS), only for late stage projects.
The Licensing Process: Maximising Values
The Way We Partner
Find out how we partner with other companies, from opportunity identification to alliance management:
CORPORATE DEVELOPMENT (CD)
Identifies partnering oportunities and starts internal evaluation
Drives the negociation process, building value through the deal-making process
collaboration between partners